Cargando…
RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
Response Evaluation Criteria In Solid Tumors (RECIST) is still the predominant criteria base for assessing tumor burden in oncology clinical trials. Despite several improvements that followed its first publication, RECIST continues to allow readers a lot of freedom in their evaluations. Notably in t...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973344/ https://www.ncbi.nlm.nih.gov/pubmed/33738548 http://dx.doi.org/10.1186/s13244-021-00976-w |